ACTU — ACTUATE THERAPEUTICS, INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1652935 ·
Last close
$0.25
Market Cap
$13.84M
52W High
$7.90
52W Low
$0.23
ADV30
459,918
Next earnings
—
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -3,439,087 -3,420,649 3,218,781 2,101,816 4,027,747
Jun 2026 0 — -4,906,588 -4,866,635 5,199,339 4,425,841 4,210,187
Mar 2026 0 — -5,705,956 -5,625,749 8,911,286 8,134,004 5,126,888
Dec 2025 0 — -4,688,473 -4,553,953 14,035,910 13,159,423 6,111,907

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-19,836,202
Investing CF
—
Financing CF
$17,769,387
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.99
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-165,100,085
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-20,433,557
Pretax Income TTM
$-20,453,807
Interest Exp TTM
$20,250
Analysts
3

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -22,495,312 -22,227,852 14,035,910 6,111,907 7,924,003 -19,206,253
Dec 2024 0 -25,160,734 -27,285,328 9,318,448 9,214,262 104,186 -21,842,648
Dec 2023 0 -24,973,829 -24,744,620 2,995,566 102,622,079 -99,626,513 -21,625,167
Dec 2022 0 -20,206,807 -20,159,401 20,483,056 95,788,488 -75,305,432 -17,794,093

TTM Snapshot

Revenues TTM
$339,838
NetIncome TTM
$-20,453,807
OpCashFlow TTM
—
Assets (Latest)
$5,199,339
Forward EPS
$-0.66

Peers — same industry

TickerNameMarket CapLastDaily %
MRKR Marker Therapeutics, Inc. $13.95M $0.84 —
INTI Inhibitor Therapeutics, Inc. $13.98M $0.08 —
SYBX SYNLOGIC, INC. $13.47M $1.10 —
TVRD Tvardi Therapeutics, Inc. $13.47M $1.01 —
CTXR Citius Pharmaceuticals, Inc. $14.24M $0.52 —

News headlines (Yahoo Finance, 1h cache)

Actuate Therapeutics Reports Positive Monotherapy Data in Aggressive Melanoma Preclinical Model with Daily Dosing of Elraglusib Oral Tablet at ENA 2026
2026-11-18 13:00 · Yahoo
Actuate Therapeutics to Present Promising Preclinical Data Demonstrating Antitumor and Immune Activation Activity of Elraglusib Oral Tablet in Advanced Melanoma Models at ENA 2026
2026-11-04 13:00 · Yahoo
Actuate Therapeutics Receives U.S. Notice of Allowance for Patent Covering Elraglusib Oral Tablets
2026-11-02 13:00 · Yahoo
Actuate Therapeutics Announces Pricing of $11.0 Million Underwritten Public Offering
2026-10-27 12:00 · Yahoo
Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-09 21:00 · Yahoo
Actuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and Daraxonrasib
2026-09-09 11:00 · Yahoo
Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program
2026-05-11 11:00 · Yahoo
Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma
2026-06-09 11:45 · Yahoo
Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors
2026-05-06 12:45 · Yahoo
Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancr
2026-04-14 12:45 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.